EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) ; Guidance on the scientific requirements for health claims related to physical performance

EFSA publication; Tetens, Inge

Link to article, DOI: 10.2903/j.efsa.2012.2817

Publication date: 2012

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

SCIENTIFIC OPINION

Guidance on the scientific requirements for health claims related to physical performance

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

European Food Safety Authority (EFSA), Parma, Italy

SUMMARY

The Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked by the European Food Safety Authority (EFSA) to draft guidance on scientific requirements for health claims related to physical performance. This guidance has been drawn from scientific opinions of the NDA Panel on such health claims. Thus, this guidance document represents the views of the NDA Panel based on the experience gained to date with the evaluation of health claims in this area. It is not intended that the document should include an exhaustive list of beneficial effects and studies/outcome measures which are acceptable. Rather, it presents examples drawn from evaluations already carried out in order to illustrate the approach of the Panel, as well as some examples which are currently under consideration within ongoing evaluations. A draft of this guidance document, endorsed by the NDA Panel on 24 November 2011, was released for public consultation from 19 December 2011 to 09 March 2012.

KEY WORDS

Health claims, scientific requirements, physical performance.

1 On request from EFSA, Question No EFSA-Q-2010-01186, adopted on 28 June 2012.
2 Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Levik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu
3 Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Levik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group on Weight Management/Satiety/Glucose and Insulin Control/Physical Performance: Kees de Graaf, Joanne Harrold, Mette Hansen, Mette Kristensen, Anders Sjödin and Inge Tetens.


© European Food Safety Authority, 2012
# TABLE OF CONTENTS

Summary ........................................................................................................................................... 1
Table of contents .............................................................................................................................. 2
Background as provided by EFSA .................................................................................................... 3
Terms of reference as provided by EFSA .......................................................................................... 3
Assessment ......................................................................................................................................... 4
1. Introduction ...................................................................................................................................... 4
2. General considerations .................................................................................................................. 5
   2.1. Beneficial physiological effects ............................................................................................... 5
   2.2. Studies/outcome measures appropriate for substantiation of claims ...................................... 5
3. Claims on physical performance .................................................................................................. 6
4. Claims on endurance capacity ...................................................................................................... 6
5. Claims on muscle function .......................................................................................................... 7
6. Claims on physiological effects which may lead to an improvement in physical performance or endurance capacity ........................................................................................................ 7
Conclusions ....................................................................................................................................... 8
Glossary and Abbreviations ............................................................................................................. 9
BACKGROUND AS PROVIDED BY EFSA
Regulation (EC) No 1924/2006⁴ harmonises the provisions that relate to nutrition and health claims and establishes rules governing the Community authorisation of health claims made on foods. According to the Regulation, health claims should only be authorised for use in the Community after a scientific assessment of the highest possible standard has been carried out by EFSA.

EFSA and its NDA Panel have been engaging in consultation with stakeholders and have published guidance on scientific substantiation of health claims since 2007⁵. Most recently, a briefing document on scientific evaluation of health claims was published for consultation in April 2010, followed by a technical meeting with experts from the food industry, Member States and the European Commission in Parma, in June 2010⁶.

Based on experiences gained with the evaluation of health claims, and to further assist applicants in preparing and submitting their applications for the authorisation of health claims, the NDA Panel is asked to develop guidance documents on the scientific requirements for the substantiation of health claims in selected areas, in addition to the guidance for the scientific substantiation of health claims related to gut and immune function (EFSA-Q-2010-01139).

TERMS OF REFERENCE AS PROVIDED BY EFSA
The NDA Panel is requested by EFSA to develop guidance documents on the scientific requirements for health claims in the following areas:

- Post-prandial blood glucose responses/blood glucose control
- Weight management, energy intake and satiety
- Protection against oxidative damage
- Cardiovascular health
- Bone, joints, and oral health
- Neurological and psychological functions
- Physical performance

Specific issues to be addressed in these guidance documents include:

- which claimed effects are considered to be beneficial physiological effects?
- which studies/outcome measures are appropriate for the substantiation of function claims and disease risk reduction claims?

Each guidance document should be subject to public consultation, and may be followed up as appropriate by scientific meetings with experts in the field.

Before the adoption of each guidance document by the NDA Panel the draft guidance shall be revised, taking into account the comments received during the public consultation. A report on the outcome of the public consultation shall be published for each guidance document. All guidance documents should be finalised by July 2012.

ASSESSMENT

1. Introduction

To assist applicants in preparing and submitting their applications for the authorisation of health claims, EFSA and in particular its Scientific Panel on Dietetic Products, Nutrition and Allergies (NDA) has ongoing consultations with stakeholders, and has published guidance on the scientific substantiation of health claims since 20077. In April 2010, a draft briefing document on the scientific evaluation of health claims was published for consultation, and was followed by a technical meeting with experts from the food industry, Member States and the European Commission in Parma, in June 2010. The draft briefing document has been transformed into a Panel output, taking into account the questions/comments received. This document constitutes the general guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims, and outlines the approach of the NDA Panel to the evaluation of health claims in general. In response to requests from industry, EFSA is engaged in further consultation with stakeholders, and is developing additional guidance on specific types of claims.

The present guidance, prepared by the NDA Panel, on the scientific requirements for the substantiation of health claims on physical performance was, prior to its finalisation, endorsed by the NDA Panel on 24 November 2011 for public consultation, which was open from 19 December 2011 to 09 March 2012. All the comments received that related to the remit of EFSA were assessed, and the guidance has been revised taking into consideration relevant comments. The comments received and a report on the outcome of the public consultation are published on the EFSA website.

The guidance document focuses on two key issues regarding the substantiation of health claims related to physical performance:

- claimed effects which are considered to be beneficial physiological effects.
- studies/outcome measures which are considered to be appropriate for the substantiation of health claims.

Issues which are related to substantiation and are common to health claims in general (e.g. characterisation of the food/constituent) are addressed in the general guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims8.

This document has been drawn from scientific opinions of the NDA Panel on health claims related to physical performance. Thus, it represents the views of the NDA Panel based on the experience gained to date with the evaluation of health claims in this area. The document should be read in conjunction with the general guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims.

It is not intended that the document should include an exhaustive list of beneficial effects and studies/outcome measures which are acceptable. Rather, it presents examples drawn from evaluations already carried out in order to illustrate the approach of the Panel, as well as some examples which are currently under consideration within ongoing evaluations. Given that health claims are often technically complex and unique, additional health relationships and outcome measures for claimed effects need to be considered in the context of a specific application. This guidance document may be updated in the future in light of additional experience gained with the evaluation of health claims.

---

2. General considerations

2.1. Beneficial physiological effects

According to Regulation (EC) No 1924/2006, the use of health claims shall only be permitted if the food/constituent for which the claim is made has been shown to have a beneficial physiological effect. In assessing each claim, the NDA Panel makes a scientific judgement on whether the claimed effect is considered to be a beneficial physiological effect in the context of the specific claim, as described in the information provided and taking into account the population group for whom the claim is intended. For function claims, a beneficial effect may relate to the maintenance or improvement of a function.

The NDA Panel considers that the population group for which health claims are intended is the general (healthy) population or specific subgroups thereof, for example, elderly people, physically active subjects, or pregnant women. Applications for claims which specify target groups other than the general (healthy) population are the subject of ongoing discussions with the Commission and Member States with regard to their admissibility.

The NDA Panel also considers whether the claimed effect is sufficiently defined to establish that the studies identified for substantiation of the claim were performed with (an) appropriate outcome measure(s) of that claimed effect. Reference to general, non-specific benefits of the nutrient or food for overall good health or health-related well-being may only be made if accompanied by a specific health claim.

2.2. Studies/outcome measures appropriate for substantiation of claims

As human studies are central for the substantiation of health claims, this document focuses in particular on such studies. In considering whether the studies provided are pertinent (i.e. studies from which conclusions can be drawn for the scientific substantiation of the claim), the NDA Panel addresses a number of questions, including:

- Whether the studies have been carried out with the food/constituent for which the claim is made. This requirement means that there should be sufficient definition of the food/constituent for which the claim is made, and of the food/constituent which has been investigated in the studies which have been provided for substantiation of the claim. The evaluation also considers how the conditions under which the human studies were performed relate to the conditions of use (e.g. quantity and pattern of consumption of the food/constituent) proposed for the claim.

- Whether the design and quality of the studies allow conclusions to be drawn for the scientific substantiation of the claim. The evaluation takes into account the hierarchy of evidence as described in the scientific and technical guidance of the EFSA NDA Panel, for example, intervention studies generally provide stronger evidence than observational studies. Intervention studies should be appropriately conducted so as to minimise bias. In observational studies adequate control for factors other than the food/constituent known to have an impact on the claimed effect is important. Each health claim is assessed separately and there is no pre-established formula as to how many or what type of studies are needed to substantiate a claim. In this regard, the reproducibility of the effect of the food/constituent as indicated by consistency between studies is an important consideration.

---

• Whether the studies have been carried out in a study group representative of the population group for which the claim is intended. Can the results obtained in the studied population be extrapolated to the target population? For studies in groups (e.g. subjects with a disease) other than the target group for a claim (e.g. the general population), the NDA Panel considers on a case-by-case basis the extent to which it is established that extrapolation from the study group to the target group is biologically plausible.

• Whether the studies used (an) appropriate outcome measure(s) of the claimed effect. For this, the NDA Panel considers what is generally accepted in the relevant research fields (e.g. guidelines published by scientific societies based on rigorous methodological approaches), and consults experts from various disciplines, as appropriate.

3. Claims on physical performance

Physical performance relates to the ability to complete certain physical tasks with higher intensity, faster, or with a higher power output. Improvement, maintenance or reduced loss of physical performance may be a beneficial physiological effect for individuals performing physical exercise for different reasons (e.g. athletes preparing for a competition or during a competition, and individuals engaged in physical work or recreational activities), but also for individuals performing common (non exercise-related) physical tasks. Information on the characteristics (e.g. type, duration and intensity) of the exercise or physical activity for which the claim is made may be important for the definition of the claimed effect (e.g. physical performance during short-term, high intensity exercise vs. longer-term, endurance performance; single exercise bout vs. repeated bouts; weight bearing vs. non-weight bearing activities) and of the target population for the claim (e.g. athletes and elderly subjects). Outcome measures of physical performance which may be appropriate for the assessment of the claimed effect in humans in the context of a particular type of exercise or physical activity should be indicated (e.g. time spent to run a certain distance, distance cycled during a time-trial, throwing distance in javelin or shot put, jumping height, walking speed and number of chair-stands in a certain time).

Some of the outcomes proposed (e.g. changes in maximum oxygen consumption (VO2max), muscle glycogen stores and substrate oxidation) are not direct measures of performance but could be used in support of a mechanism by which the food/constituent could exert the claimed effect on physical performance.

The studies provided for the scientific substantiation of the claim should reflect the conditions of use for the claim. For example, when the food/constituent is consumed relative to the physical performance test (e.g. before or during exercise), or the duration of the intervention, may be of importance.

4. Claims on endurance capacity

Endurance capacity refers to the exercise time to fatigue when exercising at a constant workload or speed, generally at intensity <80 % VO2max. An increased endurance capacity may be a beneficial physiological effect for individuals performing physical exercise which is not limited by time (e.g. recreational running, walking, swimming, cycling and fitness training).

The particular type of exercise (e.g. cycling, running and swimming) and the conditions (e.g. distance, power output and single bout vs. repeated bouts) in which endurance capacity is tested should be specified. The exercise time to fatigue under defined conditions can be assessed by using objective (e.g. cycling cadence, oxygen consumption and heart rate) or self-reported (e.g. with a validated questionnaire) measurements of physical fatigue.
Some of the outcomes proposed (e.g. changes in VO₂max, muscle glycogen stores, and substrate oxidation) are not direct measures of endurance capacity but could be used in support of a mechanism by which the food/constituent could exert the claimed effect.

5. Claims on muscle function

The improvement, maintenance or reduced loss of muscle function (e.g. muscle strength) is considered a beneficial physiological effect. Outcome measures of muscle function which may be appropriate for the assessment of the claimed effect in humans in the context of a particular type of exercise or physical activity should be indicated (e.g. one repetition maximum weight lifting, isokinetic knee extension torque and isometric handgrip strength). Also changes in muscle structure (e.g. muscle mass, muscle shape, number and type of muscle fibres, muscle damage and muscle tissue repair) contributing to the improvement, maintenance or reduced loss of muscle function (e.g. muscle strength) can be considered beneficial physiological effects. Evidence on whether (and the extent to which) specific changes in muscle structure may lead to changes in muscle function should be provided, and will be considered on a case-by-case basis.

Faster recovery from water loss, muscle fatigue, muscle soreness or muscle damage after exercise contributing to the restoration of muscle function (e.g. muscle strength), can be considered beneficial physiological effects. Subjective measures of muscle fatigue or muscle soreness may be used as supportive evidence in this context.

6. Claims on physiological effects which may lead to an improvement in physical performance or endurance capacity

Claims on specific physiological effects which may lead to an improvement in physical performance or endurance capacity have been proposed. These include, for example, reduction in perceived exertion/effort during exercise, or enhancement of water absorption during exercise. The context in which such changes may lead to changes in physical performance or endurance capacity (e.g. characteristics of the exercise or physical activity and the target population for which the claim is intended) should be provided, and will be considered on a case-by-case basis.

Outcome measures which may be appropriate for the assessment of the claimed effects in humans should be indicated. For example, validated questionnaires could be used for the assessment of perceived exertion/effort during exercise. For self-reported outcome measures, adequate blinding of subjects and investigators to the intervention is particularly important.

Claims related to changes in body composition have been addressed in the “Guidance on the scientific requirements for health claims related to appetite ratings, weight management, and blood glucose concentrations”10.

---

CONCLUSIONS

The guidance document focuses on two key issues regarding the substantiation of health claims related to physical performance:

- claimed effects which are considered to be beneficial physiological effects.
- studies/outcome measures which are considered to be appropriate for the substantiation of health claims.

The document has been drawn from scientific opinions of the NDA Panel on health claims related to physical performance. Thus, it represents the views of the NDA Panel based on the experience gained to date with the evaluation of health claims in this area.
GLOSSARY AND ABBREVIATIONS

VO₂ max  Maximum oxygen consumption